If you're developing or manufacturing medical devices, understanding FDA warning letters could save your company from public scrutiny, failed acquisitions, and regulatory shutdown. What triggers FDA warning letters, how do you prevent them, and what do you do if you receive FDA Form 483 observations? Read on.
FDA warning letters are posted online and visible to everyone: customers, patients, competitors, potential new employees. Reading between the lines of a warning letter can provide insight into problems lurking just beneath the surface of your quality system,and can signal readers to look elsewhere for a job, an acquisition, or a device.
A sought after job candidate may choose to apply elsewhere, taking their talent to your competitors. A distributor may choose a competitor’s product to market, reducing your sales. A firm preparing due diligence on your company may recommend against acquisition, citing underlying systemic issues. Ultimately, patients may find their way to this information and lose trust in your device.
A warning letter isn't just a slap on the wrist, it's a step in an escalating series of enforcement actions if your response is inadequate. It should become your top priority to not only respond to FDA, but to address the points in the warning letter in a manner which is satisfactory to the Agency, while taking immediate action to protect the public health, if warranted.
FDA warning letters can be triggered in a number of different ways.
They can come after a particularly unsuccessful FDA inspection, especially if you have received 483 findings and FDA is not satisfied with your response, or if you’ve shown a pattern of systemic issues with no improvement. An example of one such warning letter is shared below:
“This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:
Warning letters can also come when you least expect them: a number of letters are issued every year to companies marketing a device, which is considered to be a medical device by FDA, which has not followed any medical device requirements. An example of one such warning letter is shared below:
“The United States Food and Drug Administration (FDA) has learned that your firm is offering for sale in the United States the Medical Widget 2000 without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).
Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.
FDA has reviewed the labeling for your devices on your website and determined that the Medical Widget 2000 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Medical Widget 2000 is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered into interstate commerce for commercial distribution this device without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(1).”
They can also come after a BIMO inspection, either to a manufacturer, a CRO, or directly to a clinical investigator, citing violations to good clinical practices. FDA also issues warning letters for other types of products, such as tobacco, food, and drugs.
Document Your Design Process
Documentation of your design process, and the design history of your device, is critical to showing that you have designed your device to be safe and effective. Proper design documentation starts with a quality management system (QMS) and procedures for design and development, risk management, and documentation control.
Beginning your design documentation at the right time requires very careful decision-making: too early, and you risk over-burdening your feasibility testing with unnecessary paperwork; too late, and you risk not capturing important portions of your design process.
Validate Your Manufacturing Processes
Where the results of a process cannot, or will not, be fully verified by subsequent inspection and test, the process must be validated with a high degree of assurance. Once your manufacturing process has been determined for your device, take the necessary steps to perform a validation assessment for each step in the process.
For steps in the process which will not be validated, document a detailed justification rationale. For steps in the process which will be validated, design and execute the validations according to your procedures.
Provide Adequate Training for Your Employees
All participants in the design, development, manufacture, and distribution of your device require training. It is critical that training is completed, or competence is otherwise established, prior to performing a task.
Each role should have documented requirements for competencies and training requirements. If quality inspectors are using measurement equipment, they should be trained to do so. If engineers are using statistical techniques, they should have demonstrated competence to do so.
Assess your organizational competence and training requirements early as an input to hiring requirements, training plans, and organizational development planning.
Conduct Internal Audits
The key to maintaining a healthy quality management system is to perform periodic internal audits to find gaps or problem areas and fix them before FDA has the opportunity to find them during an inspection.
Make sure that you are using a qualified, but impartial, quality auditor. For most small companies or start-ups, this is likely an external or third-party auditor, as the qualified personnel are typically too involved in the processes to audit them impartially.
Place the emphasis on your internal audit program in the right areas. When you are developing your first product, you may choose to focus your internal audits in the design and development, supplier selection, or risk management areas. Internal audits of the downstream processes – complaint handling, management of distribution records, etc. – are best conducted in detail once records are available to review.
For medical device start-ups: determine if you're an FDA-regulated device, understand FDA device classification, get educated on FDA regulatory requirements, then implement required quality system procedures. If you're uncertain about FDA device classification or regulatory pathway requirements, consult FDA regulatory consultants who understand 510(k) clearance, De Novo classification, and PMA approval processes.
Know which FDA regulations and ISO standards apply to your medical device and scale your QMS appropriately. The QMS requirements for a company producing insulin pumps are not the same as for a company producing dental floss. This is why FDA regulatory expertise matters, especially with FDA's new QMSR (Quality Management System Regulation) approaching in February 2026.
Remember: your QMS must evolve with FDA guidance documents and regulation updates. A robust QMS is your first line of defense against FDA warning letters, but it must also evolve to maintain compliance. FDA regulations change, and so should your QMS. Building FDA compliance into your foundation from the start isn't just about avoiding FDA warning letters; it's about building safe and effective medical devices (along with building superior products and companies) to improve the lives of patients.
FDA warning letters are preventable with proper quality system implementation and FDA regulatory compliance expertise. If you're evaluating your FDA regulatory pathway, preparing for FDA inspections, scaling your medical device QMS, or addressing FDA compliance gaps before your next FDA audit, our FDA quality consulting team can help you build a quality-first approach that accelerates rather than impedes medical device innovation.
About the author:
Paige Sutton-Smith is Veranex Quality Management and Regulatory professional with 12 years track record in the medical device industry. Her expertise includes US regulatory approval, product design and development, process validations, V&V, complaint handling, QC strategies, QMS deployment, and auditing to FDA 21 CFR 820 / ISO 13485. She is experienced in maintaining QMS certification and FDA approvals for invasive and implantable products. Paige holds a BSc in Material Science and Engineering from Lehigh University (PA), achieved a RAC-Devices certification, is a Lean Six Sigma Black Belt, and ASQ certified as a Certified Quality Engineer. Also, Paige is certified as a NAMSA Regulatory Toxicology specialist.